# Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq)

> **NCT05415670** · — · COMPLETED · sponsor: **Geneplus-Beijing Co. Ltd.** · enrollment: 158 (actual)

## Conditions studied

- Pulmonary Nodule, Solitary
- Whole-genome Methylation Sequencing

## Interventions

- **DIAGNOSTIC_TEST:** Whole-genome Methylation Sequencing(GM-seq)

## Key facts

- **NCT ID:** NCT05415670
- **Lead sponsor:** Geneplus-Beijing Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05415670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05415670, "Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05415670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*